Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
News|Podcasts|September 8, 2023
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
Author(s)Pearl Steinzor
Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Advertisement
Florida Cancer Specialists & Research Institute's (FCS') Nathan Walcker, CEO, discusses some key strategic practices and initiatives in providing high quality community-based oncology care he has implemented at FCS.
He spoke with us at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event held in Tampa, Florida, on August 10, 2023.
Listen above or through one of these podcast services:
Advertisement
Related to this article
KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.
Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”
About one quarter of patients with overactive bladder were taking their initial oral regimen at nearly 3 years, yet most reported symptom improvement.
Advertisement
Advertisement
Trending on AJMC
1
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
2
At the Pharmacy, Affordability Connects Policy, Plans, and Patients
3
UAB Works to Deliver Cutting-Edge Cancer Therapies, Reach Every Patient
4
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia
5